To evaluate the potential of CRS for NPC screening, we combined the CRS with serum EBV VCA-/EBNA1-IgA tests for discriminating NPC cases, and estimated the PPVs and NPVs based on the test specificity, sensitivity, and NPC prevalence in southern China (Methods). The gene discussed is CD79A; the disease is nasopharyngeal carcinoma.